{"id":"ola-group-olanzapine","safety":{"commonSideEffects":[{"rate":"~30%","effect":"Weight gain"},{"rate":"~26%","effect":"Sedation"},{"rate":"~16%","effect":"Dizziness"},{"rate":"~13%","effect":"Akathisia"},{"rate":"~5-10%","effect":"Hyperglycemia/diabetes risk"},{"rate":"~10-15%","effect":"Hyperlipidemia"},{"rate":"~10%","effect":"Prolactin elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing psychotic symptoms, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. It also has activity at multiple other receptors including muscarinic, histamine H1, and alpha-adrenergic receptors, contributing to its side effect profile.","oneSentence":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:06.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute mania and maintenance)"},{"name":"Agitation associated with schizophrenia and bipolar disorder"}]},"trialDetails":[{"nctId":"NCT05590923","phase":"PHASE4","title":"Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting","status":"TERMINATED","sponsor":"The Guthrie Clinic","startDate":"2022-12-07","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Steroid-sparing therapy"],"phase":"marketed","status":"active","brandName":"OLA group: Olanzapine","genericName":"OLA group: Olanzapine","companyName":"The Guthrie Clinic","companyId":"the-guthrie-clinic","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olanzapine is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Agitation associated with schizophrenia and bipolar disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}